Sequenom Inks Deal with MultiPlan to Include MaterniT21 Plus Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sequenom today announced an expanded agreement with healthcare cost management firm MultiPlan to include the MaterniT21 Plus LDT test for fetal aneuploidies.

As a result of the deal, MultiPlan's network of 900,000 providers will have access to Sequenom's test for trisomy 21, 18, and 13. The test was launched in October.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: researchers identify the characteristic genomic features of clear cell renal cell carcinoma, and more.

A technology that has the potential to make species go extinct could be used against the Zika virus. 

University of the Republic postdoc Victor Morais says researchers should be careful of the open access journals they choose to publish in.

If science funding agencies can talk tough about sexual harassers, shouldn't they also put their talk into action?

Feb
25
Sponsored by
Omicia

This webinar will demonstrate how ACMG's recommended variant scoring and classification rules may be applied to standardize reporting on sequencing test results within and across institutions. 

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies. 

Mar
17
Sponsored by
Qiagen

This webinar will discuss Qiagen's approach to address two challenges facing NGS in the clinical research setting: lack of seamless workflow for routine clinical research use and truly relevant content to guide clinical research activities.